This trial is testing a new drug to see if it's effective and safe for patients with a certain type of lung cancer.
1 Primary · 17 Secondary · Reporting Duration: Baseline up to approximately 49 months
Active Control
Experimental Treatment
560 Total Participants · 2 Treatment Groups
Primary Treatment: Patritumab Deruxtecan · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:18 - 65 | 100.0% |
Innovative Clinical Research Institute | 100.0% |
Did not meet criteria | 50.0% |
Met criteria | 50.0% |